Valneva, a French company, announced Wednesday that it had achieved success with its Covid-19 vaccine in early laboratory studies, boosting its share price and adding to the stock of vaccines including Pfizer and Moderna that are effective against omicron as it eyes regulatory approval in Europe.
Three shots of Valneva's vaccine mitigated the omicron variant in lab tests.
2020 is the year of Bloomberg Finance.
The majority of blood samples from 30 participants in the firm's clinical trial contained neutralizing antibodies against omicron, the company said in a statement.
Valneva said that neutralization against the original strain and the delta variant was lower than against the original strain.
Juan Carlos Jaramillo, Valneva's chief medical officer, said that the results complement earlier trials on two doses of the vaccine and demonstrate its ability to address currently circulating variant of concern.
Valneva shares jumped after the announcement.
Regulatory approval. Valneva expects the shot to receive its first approvals in the first three months of 2022.
The Valneva vaccine uses a more traditional vaccine technology than popular shots from the likes of Moderna and Pfizer, and it could be a boon to encourage vaccination in those wary of the newer technologies. The company has deals to supply 60 million doses to the European Union and 1 million to the Kingdom of Bahrain, with deliveries expected to begin within the next few months. The British government terminated a 190 million dose deal with the firm for allegedly breaching supply commitments, something the company strongly denies.
The study suggests that the vaccine could be as effective as the jab.
Live updates on the coronaviruses.
All Rights Reserved © 2024
